FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558365280> ?p ?o ?g. }

• W2558365280 endingPage "50" @default.
• W2558365280 startingPage "50" @default.
• W2558365280 abstract "Yair Lotan, MD: Yair Lotan, MDIn May 2012, the U.S. Preventive Services Task Force (USPSTF) issued a grade D recommendation against the use of PSA-based screening for prostate cancer in men of all ages based on data showing that PSA-based screening contributes to overtreatment and overdiagnosis of prostate cancer (Ann Intern Med 2012;157:120-134). That recommendation has sparked controversy since it was first issued. A new study analyzed the real-world data on PSA ordering and referral practices in the years surrounding that recommendation (at UT Southwestern Medical Center) to help understand its effect on practice (Cancer DOI: 10.1002/cncr.30330). “The United States Preventive Services Task Force recommendation against PSA screening generated significant controversy,” noted study author Yair Lotan, MD, Chief of Urologic Oncology and the Helen J. and Robert S. Strauss Professor in Urology at UT Southwestern Medical Center. “We examined a large, whole-institution dataset in the years before and after the USPSTF recommendations reflecting actual practice and found that the changes in PSA use at our institution, if any, were small,” he explained. “This is more consistent with behavior seen after the vast majority of practice recommendations.” The researchers included 275,758 male ambulatory care visits between 2010 and 2015 at UT Southwestern Medical Center. The data did not reveal a significant change in the use of PSA-based screening as measured by the total number of PSA exams per ambulatory care visit. Here's why Lotan said this data matters—and has implications for providers outside of UT Southwestern. 1 Why did you decide to conduct this research—and were you surprised by what you found? “Policy regarding prostate cancer screening has important implications for men, as this is the most common cancer in men. We felt it was important to understand how the USPSTF recommendations impacted use of PSA at our large tertiary referral institution since we care for a large population of men. “In many ways, I found the results reassuring since use of PSA did not change dramatically. I was not very surprised since I have two brothers who are internists and I am aware of how many guidelines they need to keep track of in any given year. It is difficult to change their practice with each new recommendation.” 2 The actor Ben Stiller recently wrote an essay on how a PSA test “saved his life.” His PSA test appears not to be in line with the current USPSTF recommendations. If his cancer had been discovered later, does the evidence suggest he still would have responded to treatment? Would you say that Stiller's claims are warranted? “Ben Stiller's article provides important insight from a patient's perspective. He is correct that based on the USPSTF recommendation he may never have had screening. “We know that prior to PSA screening many men were diagnosed only after they experienced metastatic disease. It is hard to know the impact of delayed diagnosis in any individual patient's case—but for a young man with intermediate-risk prostate cancer, there is no question that earlier diagnosis is preferable. “In regards to current recommendations, the American Urological Association advocates for discussing the pros and cons of PSA screening with patients, which I think is a good policy so patients can make their own informed choices.” 3 What should practicing oncologists and oncology care providers outside of UT Southwestern know about this research? “Our institution's findings may not represent the nation as a whole; however, at least one survey dataset pointed to Texas as one of the states with the largest drop in PSA use, which we did not observe. With recent revelations about the flaws in studies used in the USPSTF recommendation, we hope the USPSTF will be diligent in considering the wisdom of their initial recommendation against PSA since this can have a significant impact on health of men. “Future research directions are many, including looking at provider factors that may influence PSA use and finding new ways to appropriately treat men with prostate cancer and avoid treatment in men unlikely to benefit from further treatment. There is also need to optimize recommendations regarding screening for prostate cancer and developing more accurate tests.”" @default.
• W2558365280 created "2016-12-08" @default.
• W2558365280 creator A5040593381 @default.
• W2558365280 date "2016-12-10" @default.
• W2558365280 modified "2023-09-24" @default.
• W2558365280 title "3 Questions on...PSA Screening Referrals Since the Controversial USPSTF Recommendations" @default.
• W2558365280 doi "https://doi.org/10.1097/01.cot.0000511175.23780.fc" @default.
• W2558365280 hasPublicationYear "2016" @default.
• W2558365280 type Work @default.
• W2558365280 sameAs 2558365280 @default.
• W2558365280 citedByCount "0" @default.
• W2558365280 crossrefType "journal-article" @default.
• W2558365280 hasAuthorship W2558365280A5040593381 @default.
• W2558365280 hasConcept C121608353 @default.
• W2558365280 hasConcept C126322002 @default.
• W2558365280 hasConcept C17744445 @default.
• W2558365280 hasConcept C2775941076 @default.
• W2558365280 hasConcept C2776135927 @default.
• W2558365280 hasConcept C2779377019 @default.
• W2558365280 hasConcept C2780192828 @default.
• W2558365280 hasConcept C2781406297 @default.
• W2558365280 hasConcept C29456083 @default.
• W2558365280 hasConcept C2985871740 @default.
• W2558365280 hasConcept C3116431 @default.
• W2558365280 hasConcept C35785553 @default.
• W2558365280 hasConcept C512399662 @default.
• W2558365280 hasConcept C71924100 @default.
• W2558365280 hasConceptScore W2558365280C121608353 @default.
• W2558365280 hasConceptScore W2558365280C126322002 @default.
• W2558365280 hasConceptScore W2558365280C17744445 @default.
• W2558365280 hasConceptScore W2558365280C2775941076 @default.
• W2558365280 hasConceptScore W2558365280C2776135927 @default.
• W2558365280 hasConceptScore W2558365280C2779377019 @default.
• W2558365280 hasConceptScore W2558365280C2780192828 @default.
• W2558365280 hasConceptScore W2558365280C2781406297 @default.
• W2558365280 hasConceptScore W2558365280C29456083 @default.
• W2558365280 hasConceptScore W2558365280C2985871740 @default.
• W2558365280 hasConceptScore W2558365280C3116431 @default.
• W2558365280 hasConceptScore W2558365280C35785553 @default.
• W2558365280 hasConceptScore W2558365280C512399662 @default.
• W2558365280 hasConceptScore W2558365280C71924100 @default.
• W2558365280 hasIssue "23" @default.
• W2558365280 hasLocation W25583652801 @default.
• W2558365280 hasOpenAccess W2558365280 @default.
• W2558365280 hasPrimaryLocation W25583652801 @default.
• W2558365280 hasRelatedWork W1996423854 @default.
• W2558365280 hasRelatedWork W2109046819 @default.
• W2558365280 hasRelatedWork W2168939427 @default.
• W2558365280 hasRelatedWork W2171626530 @default.
• W2558365280 hasRelatedWork W2526330449 @default.
• W2558365280 hasRelatedWork W2772533782 @default.
• W2558365280 hasRelatedWork W2966258052 @default.
• W2558365280 hasRelatedWork W3006876728 @default.
• W2558365280 hasRelatedWork W4256375936 @default.
• W2558365280 hasRelatedWork W4286449076 @default.
• W2558365280 hasVolume "38" @default.
• W2558365280 isParatext "false" @default.
• W2558365280 isRetracted "false" @default.
• W2558365280 magId "2558365280" @default.
• W2558365280 workType "article" @default.